Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
Jesús Castilla, Óscar Lecea, Carmen Martín Salas, D Quílez, Ana Miqueleiz, Camino Trobajo‐Sanmartín, Ana Navascués, Iván Martínez‐Baz, Itziar Casado, Cristina Burgui, Nerea Egüés, Guillermo Ezpeleta, Carmen Ezpeleta
Abstract
In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.